Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News aTyr Pharma Inc ATYR

Healthcare Biotechnology
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause... see more

Recent & Breaking News (NDAQ:ATYR)

Asterias Biotherapeutics to Report First Quarter Results on May 16, 2016

PR Newswire May 11, 2016

aTyr Pharma Appoints Grove Matsuoka as Senior Vice President, Product Programs and Planning

PR Newswire May 5, 2016

aTyr Pharma to Present at Upcoming May Investor Conferences

PR Newswire April 29, 2016

aTyr Pharma (LIFE) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of aTyr Pharma, Inc.; Encourages Investors to Contact the Firm for Additional Information

PR Newswire April 7, 2016

aTyr Pharma to Present at 15th Annual Needham & Company Healthcare Conference

PR Newswire April 6, 2016

PJSC Pharmsynthez Completes Follow Up and Data Analysis From a Phase 2 Study of Novel Therapeutic Vaccine Xemys(TM) for Multiple Sclerosis

Marketwired April 1, 2016

aTyr Pharma Announces Fourth Quarter 2015 Operating Results

PR Newswire March 30, 2016

aTyr Pharma Announces Encouraging Phase 1b/2 Results for Resolaris(TM) in its First Rare Myopathy Trial

PR Newswire March 30, 2016

aTyr Pharma Appoints Sanjay Shukla, MD, MS, as Chief Medical Officer

PR Newswire March 30, 2016

LifeWatch Discloses Supplemental Information on Highmark Arbitration Case

PR Newswire March 21, 2016

LifeWatch(TM) Appoints Andrew Moore as Chief Financial Officer

Canada NewsWire March 3, 2016

AliveCor Partners with LifeWatch to Expand Into Remote Patient Monitoring

PR Newswire January 12, 2016

aTyr Provides Corporate Update And Outlook For 2016

PR Newswire January 11, 2016

aTyr Pharma to Present at 34th Annual J.P. Morgan Healthcare Conference

PR Newswire January 7, 2016

aTyr Pharma Appoints Sanuj Ravindran, M.D., as Chief Business Officer

PR Newswire January 6, 2016

aTyr Pharma Added to NASDAQ Biotechnology Index

PR Newswire December 16, 2015

aTyr Pharma Selects Second IND Candidate, The First Engineered Physiocrine for GMP Process Development and for Potential Treatment of Severe Lung Diseases

PR Newswire November 11, 2015

aTyr Pharma Announces Third Quarter 2015 Operating Results

PR Newswire November 10, 2015

aTyr Pharma to Host Breakout Session at the 6th Annual World Orphan Drug Congress

PR Newswire November 10, 2015

aTyr Pharma Initiates Phase 1b/2 Clinical Trial in Patients with Early Onset FSHD

PR Newswire November 9, 2015